Seres Therapeutics

    [td_text_with_title custom_title=”Company description”]Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic® therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Seres is developing the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span metabolic, inflammatory, and infectious diseases.

    Seres Therapeutics has built a proprietary discovery and design platform that enables us to understand the dysbiosis associated with specific diseases, and to rationally design tailored therapies to establish a healthy microbiome.
    We draw upon the disciplines of systems biology and comparative genomics—as well as our expertise in isolating and characterizing microbes that are historically difficult to cultivate—to create a new class of therapies aimed at establishing a healthy microbiome. We compare a vast trove of human data from relevant disease states with that from healthy individuals to characterize specific microbiome functions that are disrupted in states of dysbiosis.

    Our deep understanding of the biology of specific microbes and the composition of the microbiome in healthy and diseased individuals allows us to identify “keystone” organisms and functional pathways whose absence or over-abundance may be driving a particular form of dysbiosis. The raw material for this effort is a proprietary library of over 9,000 microbial strain isolates derived from healthy human donors, which provides the building blocks of Ecobiotic® drugs. Ecobiotic® drugs are compositions of commensal microbes that are designed to catalyze the transition to a healthy ecology of the microbiome and treat serious human conditions including inflammatory, metabolic, and infectious diseases.[/td_text_with_title]

    Drugs

    SER-109

    SER-109 is the lead Seres Ecobiotic® microbiome therapeutic in clinical testing for the treatment of recurrent Clostridium difficile infection (CDI). SER-109 was developed utilizing the Seres Microbiome Therapeutics™ platform that provides insight into the ecologies of disease and then identifies microbial compositions that can catalyze a shift to health. CDI is a rapidly growing problem associated with [...]
    0 comments
    [td_text_with_title custom_title=”Latest post”]
    Seres Cramer Interview

    Seres Therapeutics CEO: Banking On Bacteria

    0 comments
    Seres_investment

    Seres gets orphan drug status

    CAMBRIDGE, Mass., Aug 21, 2015 (BUSINESS WIRE) — Seres Therapeutics, Inc. MCRB, +2.06% a leading microbiome therapeutics platform company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SER-109, an oral therapeutic currently in a Phase 2 clinical trial for the prevention of recurrent Clostridium difficile infection (CDI) […]

    0 comments
    Seres_investment

    Seres up 185% to 52 dollars

    InRater hotstock Seres Therapeutical, with a recent BTD status from 12 th of June,  hit the Nasdaq in full force today with a 100% increase in marketcap.  This is a stock we will be monitoring for possible investment, but being outside of the US we could not, alas, participate in the IPO. We made a […]

    0 comments
    Skærmbillede 2015-06-16 12.34.43

    Seres Therapeutics sets terms for $100 million IPO

    Seres Therapeutics, which is developing therapies that replace beneficial bacteria to treat infections, announced terms for its IPO on Tuesday. The Cambridge, MA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Seres Therapeutics would command a fully […]

    0 comments
    [/td_text_with_title]